Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 114 Florida 110 Massachusetts 66 Georgia 64 Illinois 63
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals66 Eli Lilly and Company52 AbbVie39 Bristol-Myers Squibb35 Clear sponsor filter
State
California114 Florida110 Massachusetts66 Georgia64 Illinois63
All 47 states
Target enrolment
to

Trials with a site in Massachusetts

66 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Florida, Massachusetts, Michigan, Ohio, Texas
2026-10-07
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-07-16
Recruiting
Novartis Pharmaceuticals
Phase 1
208
Massachusetts, Texas
2026-05-25
Recruiting
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Iowa, Massachusetts, Michigan, Washington
2025-10-16
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Recruiting
Novartis Pharmaceuticals
Phase 2
130
California, Florida, Massachusetts, Texas
2025-04-28
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
Novartis Pharmaceuticals
Observational
300
Massachusetts
2025-03-04
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 4
24
California, Colorado, Illinois, Massachusetts
2024-11-25
Active, closed
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, New York, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Michigan, North Carolina
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
612
California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Massachusetts
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Massachusetts
2023-08-16
Active, closed
Novartis Pharmaceuticals
Phase 1
123
California, Massachusetts, New York, Texas
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
71
California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Arizona, Colorado, Illinois, Massachusetts, Michigan, Montana, New York
2023-02-02
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Massachusetts, New York, Pennsylvania, Tennessee
2022-10-26
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Massachusetts, New York
2022-10-24
Active, closed
Novartis Pharmaceuticals
Phase 3
506
California, Florida, Georgia, Illinois, Kansas, Massachusetts, New Mexico, New York
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
66
Massachusetts, New York
2022-07-04
Active, closed
Novartis Pharmaceuticals
Phase 4
136
Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts
2022-03-02
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Florida, Indiana, Louisiana, Maryland, Massachusetts, New Jersey
2022-02-17
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Massachusetts
2022-01-27
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
153
Illinois, Massachusetts
2021-11-15
Active, closed
Novartis Pharmaceuticals
Phase 1
137
California, Illinois, Massachusetts, Ohio, Texas
2021-10-21
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Colorado, Florida, Kentucky, Massachusetts, North Carolina, Oregon, South Dakota, Tennessee
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Arizona, California, Colorado, Delaware, Idaho, Illinois, Maryland, Massachusetts
2021-09-20
Active, closed
Novartis Pharmaceuticals
Phase 1/2
164
California, Connecticut, Florida, Maryland, Massachusetts, Michigan, New York, Pennsylvania
2021-09-02
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Colorado, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts, New Jersey
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Colorado, Florida, Louisiana, Massachusetts, Missouri, Nebraska, New York, North Carolina
2021-06-15
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
California, Colorado, Louisiana, Massachusetts, Minnesota, Nevada, North Carolina, Texas
2021-03-15
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Georgia, Massachusetts, Pennsylvania, Texas
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 2
134
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Arizona, District of Columbia, Florida, Indiana, Maryland, Massachusetts, Minnesota, New York
2019-11-04
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Georgia, Massachusetts, North Carolina, Tennessee, Texas
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
California, Florida, Illinois, Kansas, Massachusetts, Pennsylvania, Tennessee, Texas
2019-06-26
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Massachusetts, Tennessee
2019-05-07
Active, closed
Novartis Pharmaceuticals
Phase 2
29
Massachusetts
2017-07-04
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Alabama, Massachusetts, Michigan, New York, Tennessee
2016-12-15
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Arizona, California, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Arizona, Massachusetts, Pennsylvania
2015-05-27
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Massachusetts, New York, Texas
2015-03-06
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
California, Florida, Massachusetts, Tennessee, Texas, Washington
2013-10-22
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Rows per page Showing 1–66 of 66
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 66 of those studies with a site in Massachusetts that also match the filters currently applied.

How many clinical trials are recruiting in Massachusetts?

23 of the 66 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 43 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Massachusetts), 66 studies
PhaseStudiesRecruitingShare
Phase 320730.3%
Phase 218527.3%
Phase 1/212618.2%
Phase 111316.7%
Phase 4304.5%
Observational111.5%
Phase 2/3111.5%

Most active sponsors

Lead sponsors with the most studies (Massachusetts)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals6623
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.